{"classes":[{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"295"}],"units":"Participants"}],"title":"Cycle 1 Day 1 Pre-Dose"},{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"63.550","value":"556.963"},{"groupId":"OG004","spread":"86.625","value":"518.944"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"280"}],"units":"Participants"}],"title":"Cycle 1 Day 1 Peak"},{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"54.432","value":"1579.040"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"67.912","value":"2097.813"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"194"}],"units":"Participants"}],"title":"Cycle 2 Day 1 Pre-Dose"},{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"39.333","value":"2011.347"},{"groupId":"OG003","spread":"59.515","value":"2331.298"},{"groupId":"OG004","spread":"62.744","value":"2117.333"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"175"}],"units":"Participants"}],"title":"Cycle 2 Day 1 Peak"},{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"42.930","value":"1865.408"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"130"}],"units":"Participants"}],"title":"Cycle 3 Day 1 Pre-Dose"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"39.300","value":"1114.046"},{"groupId":"OG003","spread":"73.596","value":"917.541"},{"groupId":"OG004","spread":"39.094","value":"1459.470"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"82"}],"units":"Participants"}],"title":"Cycle 5 Day 1 Pre-Dose"},{"categories":[{"measurements":[{"comment":"Concentrations that are below the limit of quantification (BLQ) are treated as NA","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"33.842","value":"1062.114"},{"groupId":"OG003","spread":"42.917","value":"863.539"},{"groupId":"OG004","spread":"41.166","value":"1548.018"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"54"}],"units":"Participants"}],"title":"Cycle 7 Day 1 Pre-Dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"295"}],"units":"Participants"}],"description":"Blood samples were collected for assessment of plasma concentration of Adagrasib. Data for participants for which the dose was reduced after receiving starting dose of 600 mg BID, based on physician decision is presented in separate arms.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered with study treatment in 3-week cycle and were administered 200 mg BID Adagrasib orally.","id":"OG000","title":"Adagrasib 200 mg BID"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered with study treatment in 3-week cycle and were administered 400 mg QD Adagrasib orally.","id":"OG001","title":"Adagrasib 400 mg QD"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered with study treatment in 3-week cycle and were administered 400 mg BID Adagrasib orally.","id":"OG002","title":"Adagrasib 400 mg BID"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered with study treatment in 3-week cycle and were administered 600 mg QD Adagrasib orally.","id":"OG003","title":"Adagrasib 600 mg QD"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered with study treatment in 3-week cycle and were administered 600 mg BID Adagrasib orally.","id":"OG004","title":"Adagrasib 600 mg BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK evaluable population is defined as patients who received at least one dose of active study drug and had at least one blood sample collected to assess PK concentrations","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 (Pre-Dose and Peak), Cycle 2 (Pre-Dose and Peak), Cycle 3 (Pre-Dose), Cycle 5 (Pre-Dose), Cycle 7 (Pre-Dose) (Each cycle is of 21 days)","title":"Plasma Concentration of Adagrasib","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}